BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36708586)

  • 21. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas.
    McConechy MK; Talhouk A; Li-Chang HH; Leung S; Huntsman DG; Gilks CB; McAlpine JN
    Gynecol Oncol; 2015 May; 137(2):306-10. PubMed ID: 25636458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mismatch repair deficiency screening in colorectal carcinoma by a four-antibody immunohistochemical panel in Pakistani population and its correlation with histopathological parameters.
    Hashmi AA; Ali R; Hussain ZF; Faridi N; Khan EY; Bakar SMA; Edhi MM; Khan M
    World J Surg Oncol; 2017 Jun; 15(1):116. PubMed ID: 28651545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of DNA Mismatch Repair Protein Abnormalities in Sudanese Colorectal Cancer Patients Using Immunohistochemical Methods.
    Zakout YM; Lanza G
    J Gastrointest Cancer; 2019 Sep; 50(3):530-536. PubMed ID: 29850986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An unusual phenotype occurs in 15% of mismatch repair-deficient tumors and is associated with non-colorectal cancers and genetic syndromes.
    Jaffrelot M; Farés N; Brunac AC; Laurenty AP; Danjoux M; Grand D; Icher S; Meilleroux J; Mery E; Buscail E; Maulat C; Toulas C; Vande Perre P; Chipoulet E; Bonnet D; Staub A; Guimbaud R; Selves J
    Mod Pathol; 2022 Mar; 35(3):427-437. PubMed ID: 34545179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.
    Salem ME; Bodor JN; Puccini A; Xiu J; Goldberg RM; Grothey A; Korn WM; Shields AF; Worrilow WM; Kim ES; Lenz HJ; Marshall JL; Hall MJ
    Int J Cancer; 2020 Nov; 147(10):2948-2956. PubMed ID: 32449172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
    Jin W; Wang LQ; Liu Y; Liu AJ
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
    [No Abstract]   [Full Text] [Related]  

  • 27. Lynch Syndrome in Thai Endometrial Cancer Patients.
    Manchana T; Ariyasriwatana C; Triratanachat S; Phowthongkum P
    Asian Pac J Cancer Prev; 2021 May; 22(5):1477-1483. PubMed ID: 34048176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma.
    Ye S; Zhou S; Zhong S; Shan B; Jiang W; Yang W; Cai X; Yang H
    BMC Cancer; 2022 Apr; 22(1):449. PubMed ID: 35461222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histopathological and genetic features of mismatch repair-deficient high-grade prostate cancer.
    Wyvekens N; Tsai HK; Sholl LM; Tucci J; Giannico GA; Gordetsky JB; Hirsch MS; Barletta JA; Acosta AM
    Histopathology; 2022 Jun; 80(7):1050-1060. PubMed ID: 35395112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigation of discrepant mismatch repair immunohistochemistry and microsatellite instability polymerase chain reaction test results for gynecologic cancers using next-generation sequencing.
    Smithgall MC; Remotti H; Hsiao SJ; Mansukhani M; Liu-Jarin X; Fernandes H
    Hum Pathol; 2022 Jan; 119():41-50. PubMed ID: 34666078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.
    Buchanan DD; Tan YY; Walsh MD; Clendenning M; Metcalf AM; Ferguson K; Arnold ST; Thompson BA; Lose FA; Parsons MT; Walters RJ; Pearson SA; Cummings M; Oehler MK; Blomfield PB; Quinn MA; Kirk JA; Stewart CJ; Obermair A; Young JP; Webb PM; Spurdle AB
    J Clin Oncol; 2014 Jan; 32(2):90-100. PubMed ID: 24323032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An exploration of gastric cancer with heterogeneous mismatch repair status.
    Wang X; Jiang K; Hu Y; Zhao X; Yin L; Diao X; Ma X; Xu Y; Bai Y; Zhang Y; Li Z; Sun Y
    Virchows Arch; 2023 Mar; 482(3):517-523. PubMed ID: 36754896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of Mismatch Repair Proteins in Early and Advanced Gastric Cancer in Poland.
    Karpińska-Kaczmarczyk K; Lewandowska M; Ławniczak M; Białek A; Urasińska E
    Med Sci Monit; 2016 Aug; 22():2886-92. PubMed ID: 27527654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in genetic technologies result in improved diagnosis of mismatch repair deficiency in colorectal and endometrial cancers.
    Evans DG; Lalloo F; Ryan NA; Bowers N; Green K; Woodward ER; Clancy T; Bolton J; McVey RJ; Wallace AJ; Newton K; Hill J; McMahon R; Crosbie EJ
    J Med Genet; 2022 Apr; 59(4):328-334. PubMed ID: 33452216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Correlation between mismatch-repair protein expression and clinicopathologic features in 658 colorectal cancers].
    Hu XR; Xu C; Kang Y; Wang T; Zhang Y; Yang XH
    Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):827-833. PubMed ID: 30423605
    [No Abstract]   [Full Text] [Related]  

  • 36. Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens.
    Chapel DB; Yamada SD; Cowan M; Lastra RR
    Gynecol Oncol; 2018 Jun; 149(3):570-574. PubMed ID: 29656794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Correlation of Histopathologic Parameters With Mismatch Repair Protein-deficient Subgroups and MLH1 Methylation in Endometrial Carcinomas.
    Soylemez T; Kir G; Olgun ZC; Dur SR; Tosun MI; Ankarali H; Demircan B; Kaya IA; Karateke A
    Int J Gynecol Pathol; 2022 Sep; 41(5):484-495. PubMed ID: 34723847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of the immunohistochemical analysis of DNA mismatch-repair proteins in endometrial hyperplasia.
    Missaoui N; Boukhari N; Limam S; Hmissa S; Mokni M
    Acta Histochem; 2020 Apr; 122(3):151505. PubMed ID: 31955910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.
    Goodfellow PJ; Billingsley CC; Lankes HA; Ali S; Cohn DE; Broaddus RJ; Ramirez N; Pritchard CC; Hampel H; Chassen AS; Simmons LV; Schmidt AP; Gao F; Brinton LA; Backes F; Landrum LM; Geller MA; DiSilvestro PA; Pearl ML; Lele SB; Powell MA; Zaino RJ; Mutch D
    J Clin Oncol; 2015 Dec; 33(36):4301-8. PubMed ID: 26552419
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Correlation of NTRK genetic fusions with mismatch repair protein deletion in patients with colorectal cancer].
    Pu XH; Gao FP; Wu HY; Fu Y; Fan XS
    Zhonghua Bing Li Xue Za Zhi; 2022 Feb; 51(2):103-107. PubMed ID: 35152627
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.